Browse the evidence

Participants without type 2 diabetes (T2D) achieved significantly greater weight loss than those with T2D, with a median weight loss of 11.21% vs 5.48%, P < 0.001.

Practitioners should consider diabetes status when setting weight loss expectations for patients.

Tirzepatide was associated with greater weight loss compared with semaglutide, with a median weight loss of 8.60% vs 5.62%, P = 0.023.

Clinicians may prefer tirzepatide over semaglutide for better weight loss outcomes.

Younger age, tirzepatide use, and GLP1 treatment naivety were identified as determinants of faster achievement of ≥10% weight loss.

Understanding these determinants can help tailor weight loss strategies for individuals.

Adding testosterone undecanoate to tirzepatide in late responders resulted in significantly greater body weight and fat mass reduction compared to tirzepatide monotherapy (P<0.05).

Clinicians may consider adding testosterone therapy to enhance weight loss outcomes in specific patient populations.

Testosterone undecanoate addition led to significant lean body mass recovery compared to tirzepatide monotherapy (66.1±3.1 kg vs. 63.4±3.0 kg, P<0.01).

Adding testosterone therapy may help preserve or enhance muscle mass in patients struggling with weight loss.

Approximately two-thirds of patients showed stable weight or continued weight loss during the 6 months following their last semaglutide or tirzepatide prescription.

Practitioners can expect that a significant portion of patients may maintain or lose weight after discontinuing GLP-1RA.

Tirzepatide treatment was associated with a mean percentage weight change of -13.3% for 5 mg and -21.3% for 15 mg compared to placebo from randomization to 72 weeks among participants using weight-inducing medications in SURMOUNT-1.

Practitioners can consider tirzepatide as an effective option for weight loss in patients requiring weight-inducing medications.

In SURMOUNT-3, the mean percentage weight change for the maximum tolerated dose of tirzepatide was -26.1% from randomization to 72 weeks among participants using weight-inducing medications.

Practitioners can consider higher doses of tirzepatide for significant weight loss in patients on weight-inducing medications.

Tirzepatide treatment was associated with weight loss comparable to primary study results among participants taking weight-inducing medications.

Practitioners can confidently recommend tirzepatide for weight loss in patients on weight-inducing medications.

Eine Therapie mit GLP-1-RA kann erfolgreich sein, wenn sie mit nicht-medikamentösen Maßnahmen kombiniert wird.

Die Kombination von GLP-1-RA mit Lebensstiländerungen ist entscheidend für den Therapieerfolg.

Metabolic therapies like tirzepatide can reduce weight and improve OSA severity.

Incorporating metabolic therapies may enhance treatment strategies for patients with obesity and OSA.

GLP-1 receptor agonists achieve clinically significant weight loss of 15–22.5% total body weight.

GLP-1 RAs can be considered effective options for achieving significant weight loss in obesity management.

GLP-1 receptor agonists and dual glucose-dependent insulinotropic polypeptide/GLP-1 receptor agonists provide clinically meaningful weight loss of approximately 15%–21% at 68–72 weeks in major trials.

Practitioners can expect significant weight loss in patients using GLP-1 therapies over the specified duration.

Semaglutide reduces the composite of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke by 20% in adults with established cardiovascular disease.

GLP-1 therapies may also provide cardiovascular benefits, which is important for patient management.

Incretin-based therapies have transformed the management of obesity and type 2 diabetes, with GLP-1RAs achieving levels of weight loss that begin to narrow the gap with metabolic surgery in selected populations.

Practitioners should consider incretin-based therapies as effective options for weight management in patients with obesity and type 2 diabetes.

Participants using the program plus medication were more likely to achieve clinically significant weight loss, with odds ratios ranging from 1.46 to 2.57 for ≥5% weight loss across timepoints.

Integrating a behavioral support app with GLP-1 RA treatment can significantly enhance weight loss outcomes.

Progress logging was associated with greater weight loss over time.

Encouraging users to log their progress can lead to better weight loss results.

Medication type was the strongest determinant of weight loss over time, with tirzepatide producing greater early reductions.

Choosing the right GLP-1 RA can significantly impact weight loss success.

Proper maintenance of skeletal muscle mass is essential to prevent sarcopenia and ensure health and quality of life as aging progresses.

Emphasizing muscle maintenance can improve health outcomes in aging populations.

The combination of resistance exercise and adequate protein intake is important for maintaining or increasing muscle mass.

Combining resistance training with adequate protein intake is crucial for muscle maintenance and growth.

Chronic ketone ester intake may blunt overreaching symptoms during short-term endurance training overload.

Practitioners may consider ketone esters to mitigate overreaching in endurance training.

Retatrutide yields a 24.2% reduction in total body weight at 48 weeks with 63% of participants achieving a total body weight loss of ≥20%.

Retatrutide may be an effective option for significant weight loss in patients.

Protein supplementation resulted in a significant positive effect on muscle mass with a weighted mean difference of 0.47 kg (95% CI, 0.18-0.75 kg; P < .001).

Practitioners should consider recommending protein supplementation to enhance muscle mass in healthy individuals.

Protein supplementation positively affected upper body strength.

Practitioners may recommend protein supplementation to improve upper body strength in healthy individuals.